Gennex Laboratories Limited

GENNEX6

INE509C01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:25:44 31/05/2024 BST			5-day change	1st Jan Change
17.16 ^INR	+1.00%		-9.06%	+2.08%

02-14	Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
02-14	Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	CI

Gennex Laboratories Limited completed the acquisition of 6.73% minority stake in Deccan Remedies Limited.

March 28, 2023

Gennex Laboratories Limited (BSE:531739) intends to acquire additional 6.73% minority stake in Deccan Remedies Limited on December 24, 2021. Post acquisition, will hold 51% stake in Deccan Remedies Limited. Gennex Laboratories Limited (BSE:531739) agreed to acquire additional 6.73% minority stake in Deccan Remedies Limited on January 4, 2022.

Gennex Laboratories Limited (BSE:531739) completed the acquisition of 6.73% minority stake in Deccan Remedies Limited on March 1, 2023.

Latest news about Gennex Laboratories Limited

Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	02-14	CI
Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director	02-01	CI
Gennex Laboratories Gets Good Manufacturing Practices Certificate from Indian Regulator	12-13	MT
Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd	12-01	CI
Gennex Laboratories Board to Consider Raising Funds Via Equity	11-29	MT
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Gennex Laboratories Gets Permission to Manufacture, Sell Fexofenadine, Minoxidil	10/08/23	MT
Gennex Laboratories Limited Obtains Approval of Additional Products from Drug Control Administration, Government of Telangana	09/08/23	CI
Gennex Laboratories Gets WHO-GMP Certification from Drug Control Administration, Government of Telangana	11/07/23	MT
Gennex Laboratories Arm Gets Drug Manufacturing License	02/06/23	MT
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	31/05/23	CI
Gennex Laboratories Limited Appoints Dinesh Kumar Kejriwal as Company Secretary & Compliance Officer	20/04/23	CI
Gennex Laboratories Limited completed the acquisition of 6.73% minority stake in Deccan Remedies Limited.	28/02/23	CI
Gennex Laboratories Limited Approves the Acceptance of Resignation of Rajesh Vankadara as Company Secretary & Compliance Officer	14/02/23	CI
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023	07/02/23	CI
Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/08/22	CI
Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana	27/07/22	CI
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/05/22	CI
Gennex Laboratories Board OKs Up to $5.3 Million Rights Issue	06/04/22	MT
Gennex Laboratories Board to Consider Fundraising Via Debt or Equity Offering	28/03/22	MT
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Gennex Laboratories Limited agreed to acquire additional 6.73% minority stake in Deccan Remedies Limited.	23/12/21	CI

Chart Gennex Laboratories Limited

Duration

Period

More charts

Company Profile

Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing bulk drugs, intermediaries, and biotech products. The Company has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The Company operates through the Pharmaceutical Products (Bulk Drugs) segment. The Company's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The Company has manufacturing facilities in India which cater to both domestic and international markets.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENNEX LABORATORIES LIMITED	+2.08%	46.77M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B